

ModernGraham Valuation

Company Name:

Company Ticker REGN

Date of Analysis

Regeneron
Pharmaceuticals Inc

2/19/2019



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$45,315,883,992	Pass
2. Sufficiently Strong Financial Condition	Current Ratio > 2	4.47	Pass
3. Earnings Stability	Positive EPS for 10 years prior		Fail
4. Dividend Record	Dividend Payments for 10 years prior		Fail
5. Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	1470.07%	Pass
6. Moderate PEmg Ratio	PEmg < 20	29.09	Fail
7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	5.53	Fail

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	4.47	Pass
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	0.00	Pass
3. Earnings Stability	Positive EPS for 5 years prior		Pass
4. Dividend Record	Currently Pays Dividend		Fail
5. Earnings Growth	EPSmg greater than 5 years ago Score		Pass

Suitability

Defensive	No
Enterprising	Yes

Stage 2: Determination of Intrinsic Value

EPSmg	\$14.51
MG Growth Estimate	15.00%
MG Value	\$558.51
MG Value based on 3% Growth	\$210.35
MG Value based on 0% Growth	\$123.31
Market Implied Growth Rate	10.30%

MG Opinion

Current Price	\$422.07
% of Intrinsic Value	75.57%
Opinion	Fairly Valued
MG Grade	C+


Stage 3: Information for Further Research





Net Current Asset Value (NCAV)	\$30.26
Graham Number	\$170.59
PEmg	29.09
Current Ratio	4.47
PB Ratio	5.53
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend Growth	0

Useful Links:

ModernGraham tagged articles	Morningstar
Google Finance	MSN Money
Yahoo Finance	Seeking Alpha
GuruFocus	SEC Filings

EPS History		EPSmg History	
Next Fiscal Year Estimate	\$16.10	Next Fiscal Year Estimate	\$14.51
Dec2018	\$21.29	Dec2018	\$12.33
Dec2017	\$10.34	Dec2017	\$7.25
Dec2016	\$7.70	Dec2016	\$5.58
Dec2015	\$5.52	Dec2015	\$4.12
Dec2014	\$2.98	Dec2014	\$2.92
Dec2013	\$3.72	Dec2013	\$2.33
Dec2012	\$6.75	Dec2012	\$1.16
Dec2011	-\$2.45	Dec2011	-\$1.56
Dec2010	-\$1.26	Dec2010	-\$1.18
Dec2009	-\$0.85	Dec2009	-\$1.22
Dec2008	-\$1.00	Dec2008	-\$1.29
Dec2007	-\$1.59	Dec2007	-\$1.39
Dec2006	-\$1.77	Dec2006	-\$1.37
Dec2005	-\$1.71	Dec2005	-\$1.30
Dec2004	\$0.74	Dec2004	-\$1.17
Dec2003	-\$2.13	Dec2003	-\$1.96
Dec2002	-\$2.83	Balance Sheet Information 12/1/2018	
Dec2001	-\$1.81	Total Current Assets	\$6,447,600,000
Dec2000	-\$0.66	Total Current Liabilities	\$1,442,800,000
Dec1999	-\$0.74	Long-Term Debt	\$0
		Total Assets	\$11,734,500,000
		Intangible Assets	\$0
		Total Liabilities	\$2,977,200,000
		Shares Outstanding (Diluted Average)	114,671,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor. The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

- Other ModernGraham posts about the company**
- [Regeneron Pharmaceuticals Inc Valuation – April 2018 \\$REGN](#)
 - [Regeneron Pharmaceuticals Inc Valuation – November 2016 \\$REGN](#)
 - [Regeneron Pharmaceuticals Inc Valuation – August 2016 \\$REGN](#)
 - [Regeneron Pharmaceuticals Inc. Annual Valuation – 2015 \\$REGN](#)
 - [16 Companies in the Spotlight this Week – 4/19/14](#)

- Other ModernGraham posts about related companies**
- [Alexion Pharmaceuticals Inc Valuation – February 2019 \\$ALXN](#)
 - [Vertex Pharmaceuticals Inc Valuation – February 2019 \\$VRTX](#)
 - [Perrigo Company Valuation – February 2019 \\$PRGO](#)
 - [Eli Lilly and Co Valuation – January 2019 \\$LLY](#)
 - [Zoetis Inc Valuation – January 2019 \\$ZTS](#)
 - [Gilead Sciences Inc Valuation – January 2019 \\$GILD](#)
 - [Pfizer Inc Valuation – November 2018 \\$PFE](#)
 - [Nektar Therapeutics Valuation – November 2018 \\$NKTR](#)
 - [Merck & Co Inc Valuation – November 2018 \\$MRK](#)
 - [Ligand Pharmaceuticals Inc Valuation – September 2018 \\$LGND](#)